Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.

about

Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.

Item

http://www.wikidata.org/entity/Q38306139

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dose modification of anti-TNF ...... view of observational studies.

@en

type

Item

label

Dose modification of anti-TNF ...... view of observational studies.

@en

prefLabel

Dose modification of anti-TNF ...... view of observational studies.

@en

P1476

Dose modification of anti-TNF ...... view of observational studies.

@en

P2093

Joaquín Borrás-Blasco

http://www.w3.org/2001/XMLSchema#string

P2860

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.

Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).

Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study.

Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.

Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS).

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.

Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective

Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting.

Economic consequences of established rheumatoid arthritis and its treatment.

P304

71-79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737167.2015.967219

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Navarro Ruiz

P577

2015-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25555555

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.

about

Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921